The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Novartis has been boosted by data from a new study which shows that its new combination antihypertensive Exforge lowers blood pressure in twice as many patients than those on amlodipine alone.

Novartis has said it will pay $245 million to resolve civil litigation in the US, which accuses it of a 'pay for delay' scheme involving generics of its high blood pressure therapy Exforge. The case ...

Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in separate settlements with direct purchasers, ...

Exforge HCT approved for hypertension The FDA has approved Novartis' Exforge HCT (amlodipine/valsartan/hydrochlorothiazide) tablets, a combination product containing ...

EAST HANOVER, N.J., Aug. 4 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved two single-pill combination medications, Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge ...

NEW YORK, Dec 28 (Reuters) - Novartis AG (NOVN.S), opens new tab said on Wednesday it will pay $245 million to end antitrust litigation accusing the Swiss drugmaker of trying to delay the launch in ...

Feb 23 (Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million to settle claims by health plans and consumers that it schemed to delay the U.S. launch of generic competition for its ...

Deal is part of $245 million package announced last year Novartis, Endo unit accused of conspiring to keep competitors out Feb 23 (Reuters) - Swiss drugmaker Novartis AG has agreed to pay $30 million ...